KBI BioPharma says its cell culture system that could be boost to drug development efforts has moved to the applied development phase.

The Centrifugal Bioreactor is a proprietary bioprocessing technology developed by the Durham-based contract biopharmaceutical process development, production and technology company.

“We are extremely pleased to be able to advance this important biopharmaceutical production technology from a research setting into applications development,” said Tony Laughrey, chief executive officer and president of KBI BioPharma, in a statement. “We believe that the CBR has the potential to dramatically reduce the cost of production for biopharmaceuticals for both clinical trial quantities and market supply and may represent a paradigm changing approach to production of these important molecules.”

Further development will be done under the direction of Firoz Mistry, vice president cell culture and fermentation operations.

The company said it will undertake research collaborations with a “limited number” of other firms that are developing recombinant proteins or monoclonal antibodies in order to demonstrate performance of the CBR technology in production of specific products.

KBI BioPharma: www.kbibiopharma.com